Susquehanna International Group
FSTX

Susquehanna International Group’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Susquehanna International Group’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-144,700
Closed -$915K – 14065
2022
Q4 		$915K Sell
144,700
-99,900
-41% -$553K ﹤0.01% 6387
2022
Q3 		$1.25M Sell
244,600
-44,100
-15% -$277K ﹤0.01% 6053
2022
Q2 		$1.81M Buy
+288,700
New +$972K ﹤0.01% 5123
2022
Q1 		– Sell
-22,900
Closed -$115K – 14377
2021
Q4 		$115K Buy
22,900
+12,900
+129% +$77.8K ﹤0.01% 12045
2021
Q3 		$73K Buy
+10,000
New +$68.6K ﹤0.01% 12209

Susquehanna International Group's FSTX Position: Q1 2023 in Review

Susquehanna International Group sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2023, closing a stake of 55,066 shares — an estimated $348K sold.

Susquehanna International Group first reported a position in FSTX in Q4 2016 and held it in 8 quarters. The position peaked at $926K in Q2 2022. 0 funds tracked by Wall St. Rank hold FSTX as of Q1 2023.

  • Susquehanna International Group reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Susquehanna International Group sold 55,066 F-star Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $348K.
  • Susquehanna International Group first reported a position in F-star Therapeutics, Inc. Common Stock in Q4 2016 and held it in 8 quarters.
  • Susquehanna International Group's F-star Therapeutics, Inc. Common Stock position peaked at $926K in Q2 2022.
  • 0 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Susquehanna International Group's 13F filing for Q1 2023, filed 16 May 2023.